COVID-19 Research Paper Volume 13, Issue 2 pp 1591—1607

Coagulation dysfunction in ICU patients with coronavirus disease 2019 in Wuhan, China: a retrospective observational study of 75 fatal cases

The dynamic changes in coagulation function over 5 consecutive days using laboratory markers in critical type COVID-19 patients with or without anticoagulation treatment. (A) D-dimer (B) FDP (C) PT (D) PTA (E) APTT (F) AT-III (G) ALB (H) PLT. *P**PSupplementary Table 2. COVID-19: coronavirus disease 2019, FDP: fibrinogen degradation products, PT: prothrombin time, PTA: PT activity, APTT: activated partial thromboplastin time, AT-III: antithrombin III, ALB: albumin, PLT: platelet.

Figure 3. The dynamic changes in coagulation function over 5 consecutive days using laboratory markers in critical type COVID-19 patients with or without anticoagulation treatment. (A) D-dimer (B) FDP (C) PT (D) PTA (E) APTT (F) AT-III (G) ALB (H) PLT. *P<0.05, **P<0.01 with anticoagulant group vs. non-anticoagulant group, all P values can be found in Supplementary Table 2. COVID-19: coronavirus disease 2019, FDP: fibrinogen degradation products, PT: prothrombin time, PTA: PT activity, APTT: activated partial thromboplastin time, AT-III: antithrombin III, ALB: albumin, PLT: platelet.